Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (CYCC), a Delaware corporation, on January 10, 2020. The report addresses a critical corporate governance event regarding the company's listing status on The Nasdaq Stock Market LLC. Note: The request metadata references "Bio Green Med Solution, Inc.," but the filing text explicitly identifies the registrant as Cyclacel Pharmaceuticals, Inc.
Key Financial Metrics
This filing is a current report regarding a listing deficiency and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Delisting Notice: The company received notice from Nasdaq that its Common Stock and Preferred Stock are subject to delisting.
- Compliance Failure: The company failed to regain compliance with Nasdaq Listing Rule 5450(a)(1) (the "Bid Price Rule") by the deadline of January 6, 2020.
- Historical Context: The company had previously received a notice of non-compliance on January 11, 2019, and was granted two 180-day compliance periods, the second of which expired on January 6, 2020.
Outlook, Risks, and Management Commentary
- Appeal Process: Management intends to timely appeal Nasdaq's determination to the Nasdaq Listing Qualifications Panel.
- Proposed Remedy: The company plans to present a strategy to regain compliance, which includes effecting a reverse stock split.
- Timeline: The appeal will automatically stay delisting actions. If successful, the Panel may grant an additional 180 calendar days (until July 6, 2020) to satisfy the bid price requirement.
- Risk Factors: There is no assurance that the Panel will grant the request for continued listing. Failure to maintain listing could result in the stock being delisted from Nasdaq.
Investor Verification Checklist
- Verify the current trading status of CYCC and CYCCP on Nasdaq to confirm if the delisting stay is active.
- Monitor for subsequent filings (e.g., 8-K or press releases) detailing the outcome of the appeal to the Listing Qualifications Panel.
- Review the company's plan for the reverse stock split, including the proposed ratio and expected implementation date.
- Check the closing bid price of the stock to assess the likelihood of meeting the $1.00 minimum requirement within the potential extension period.